ALNY - Alnylam Pharmaceuticals Non-GAAP EPS of -$2.03 misses by $0.69 revenue of $224.82M misses by $31.24M
- Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q2 Non-GAAP EPS of -$2.03 misses by $0.69 .
- Revenue of $224.82M (+1.9% Y/Y) misses by $31.24M .
- Cash, cash equivalents and marketable securities were $2.11 billion as of June 30, 2022, compared to $2.44 billion as of December 31, 2021, with the decrease primarily due to our operating loss in the second quarter of 2022.
- Reiterated 2022 Financial Guidance, Including Combined Net Product Revenues of $870-$930 Million
For further details see:
Alnylam Pharmaceuticals Non-GAAP EPS of -$2.03 misses by $0.69, revenue of $224.82M misses by $31.24M